First Human Test of CRISPR Proposed
By Antonio Regalado,
MIT Technology Review
| 06. 16. 2016
A federal safety board next week will consider the first human use of the gene-editing technology CRISPR, according to the National Institutes of Health.
The proposed treatment is an immune therapy in which a patient’s own blood cells will be removed and genetically altered using the technology, a type of molecular scissors able to precisely cut DNA.
The cancer treatment, in development by the University of Pennsylvania, is designed to target myeloma, melanoma, and sarcomas, according to the NIH.
Continue reading on MIT Technology Review
Image via Flickr
Related Articles
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Anna Rogers, Mother Jones | 06.19.2026
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
